Francois Gessier
Overview
Explore the profile of Francois Gessier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
548
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang X, Gessier F, Perozzo R, Stojkov D, Hosseini A, Amirshahrokhi K, et al.
J Immunol
. 2020 Aug;
205(6):1653-1663.
PMID: 32796025
Cytokine-primed neutrophils can undergo a nonapoptotic type of cell death using components of the necroptotic pathway, including receptor-interacting protein kinase-3 (RIPK3), mixed lineage kinase-like (MLKL) and NADPH oxidase. In this...
2.
Angst D, Gessier F, Janser P, Vulpetti A, Walchli R, Beerli C, et al.
J Med Chem
. 2020 Feb;
63(10):5102-5118.
PMID: 32083858
Bruton's tyrosine kinase (BTK), a cytoplasmic tyrosine kinase, plays a central role in immunity and is considered an attractive target for treating autoimmune diseases. The use of currently marketed covalent...
3.
Pulz R, Angst D, Dawson J, Gessier F, Gutmann S, Hersperger R, et al.
ACS Med Chem Lett
. 2019 Oct;
10(10):1467-1472.
PMID: 31620235
Bruton's tyrosine kinase (BTK) is a member of the TEC kinase family and is selectively expressed in a subset of immune cells. It is a key regulator of antigen receptor...
4.
Kallen J, Izaac A, Chau S, Wirth E, Schoepfer J, Mah R, et al.
ChemMedChem
. 2019 May;
14(14):1305-1314.
PMID: 31066983
Hdm2 (human MDM2, human double minute 2 homologue) counteracts p53 function by direct binding to p53 and by ubiquitin-dependent p53 protein degradation. Activation of p53 by inhibitors of the p53-Hdm2...
5.
Jeay S, Gaulis S, Ferretti S, Bitter H, Ito M, Valat T, et al.
Elife
. 2016 Nov;
5.
PMID: 27852439
No abstract available.
6.
Holzer P, Masuya K, Furet P, Kallen J, Valat-Stachyra T, Ferretti S, et al.
J Med Chem
. 2015 Jul;
58(16):6348-58.
PMID: 26181851
As a result of our efforts to discover novel p53:MDM2 protein-protein interaction inhibitors useful for treating cancer, the potent and selective MDM2 inhibitor NVP-CGM097 (1) with an excellent in vivo...
7.
Gessier F, Kallen J, Jacoby E, Chene P, Stachyra-Valat T, Ruetz S, et al.
Bioorg Med Chem Lett
. 2015 Jul;
25(17):3621-5.
PMID: 26141769
Blocking the interaction between the p53 tumor suppressor and its regulatory protein MDM2 is a promising therapeutic concept under current investigation in oncology drug research. We report here the discovery...
8.
Choi H, Rucker P, Wang Z, Fan Y, Albaugh P, Chopiuk G, et al.
ACS Med Chem Lett
. 2015 May;
6(5):562-7.
PMID: 26005534
Deregulated kinase activities of tropomyosin receptor kinase (TRK) family members have been shown to be associated with tumorigenesis and poor prognosis in a variety of cancer types. In particular, several...
9.
Jeay S, Gaulis S, Ferretti S, Bitter H, Ito M, Valat T, et al.
Elife
. 2015 May;
4.
PMID: 25965177
Biomarkers for patient selection are essential for the successful and rapid development of emerging targeted anti-cancer therapeutics. In this study, we report the discovery of a novel patient selection strategy...
10.
Rutkowska A, Preuss I, Gessier F, Sailer A, Dev K
Glia
. 2014 Oct;
63(2):341-51.
PMID: 25297897
The G protein-coupled receptor EBI2 (Epstein-Barr virus-induced gene 2) is activated by 7α, 25-dihydroxycholesterol (7α25HC) and plays a role in T cell-dependant antibody response and B cell migration. Aberrant EBI2...